ARGX vs. THC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ARGX and THC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ARGX trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, THC is a standard domestic listing.
| Symbol | ARGX | THC |
|---|---|---|
| Company Name | argenx SE | Tenet Healthcare Corporation |
| Country | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 41.33 billion USD | 16.07 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | May 18, 2017 | March 17, 1980 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of ARGX and THC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ARGX | THC |
|---|---|---|
| 5-Day Price Return | 1.49% | 5.56% |
| 13-Week Price Return | 7.13% | 8.76% |
| 26-Week Price Return | -8.03% | 36.21% |
| 52-Week Price Return | 20.32% | 16.49% |
| Month-to-Date Return | -5.96% | 12.81% |
| Year-to-Date Return | -6.83% | 44.13% |
| 10-Day Avg. Volume | 0.08M | 0.97M |
| 3-Month Avg. Volume | 0.08M | 1.56M |
| 3-Month Volatility | 36.77% | 36.93% |
| Beta | 0.75 | 1.52 |
Profitability
Return on Equity (TTM)
ARGX
17.59%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 17.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
THC
37.25%
Health Care Providers & Services Industry
- Max
- 26.03%
- Q3
- 13.74%
- Median
- 8.26%
- Q1
- 4.13%
- Min
- -3.62%
THC’s Return on Equity of 37.25% is exceptionally high, placing it well beyond the typical range for the Health Care Providers & Services industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
ARGX
-23.60%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
ARGX has a negative Net Profit Margin of -23.60%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
THC
7.17%
Health Care Providers & Services Industry
- Max
- 12.40%
- Q3
- 5.93%
- Median
- 1.96%
- Q1
- 0.93%
- Min
- -6.10%
A Net Profit Margin of 7.17% places THC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ARGX
-40.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
ARGX has a negative Operating Profit Margin of -40.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
THC
17.77%
Health Care Providers & Services Industry
- Max
- 19.05%
- Q3
- 10.21%
- Median
- 4.22%
- Q1
- 1.98%
- Min
- -4.27%
An Operating Profit Margin of 17.77% places THC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ARGX | THC |
|---|---|---|
| Return on Equity (TTM) | 17.59% | 37.25% |
| Return on Assets (TTM) | 15.24% | 5.11% |
| Net Profit Margin (TTM) | -23.60% | 7.17% |
| Operating Profit Margin (TTM) | -40.34% | 17.77% |
| Gross Profit Margin (TTM) | 90.83% | 82.36% |
Financial Strength
Current Ratio (MRQ)
ARGX
5.60
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
ARGX’s Current Ratio of 5.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
THC
1.71
Health Care Providers & Services Industry
- Max
- 2.01
- Q3
- 1.49
- Median
- 1.30
- Q1
- 0.94
- Min
- 0.17
THC’s Current Ratio of 1.71 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio (MRQ)
ARGX
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
ARGX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
THC
3.51
Health Care Providers & Services Industry
- Max
- 2.17
- Q3
- 1.18
- Median
- 0.74
- Q1
- 0.45
- Min
- 0.00
With a Debt-to-Equity Ratio of 3.51, THC operates with exceptionally high leverage compared to the Health Care Providers & Services industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
ARGX
-81.88
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
ARGX has a negative Interest Coverage Ratio of -81.88. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
THC
10.27
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.15
- Median
- 5.45
- Q1
- 2.04
- Min
- -4.44
THC’s Interest Coverage Ratio of 10.27 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ARGX | THC |
|---|---|---|
| Current Ratio (MRQ) | 5.60 | 1.71 |
| Quick Ratio (MRQ) | 4.92 | 1.54 |
| Debt-to-Equity Ratio (MRQ) | 0.01 | 3.51 |
| Interest Coverage Ratio (TTM) | -81.88 | 10.27 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 5.38%
- Q3
- 2.22%
- Median
- 0.55%
- Q1
- 0.00%
- Min
- 0.00%
THC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ARGX
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
THC
0.00%
Health Care Providers & Services Industry
- Max
- 186.69%
- Q3
- 74.82%
- Median
- 26.76%
- Q1
- 0.00%
- Min
- 0.00%
THC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ARGX | THC |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ARGX
31.14
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
ARGX’s P/E Ratio of 31.14 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
THC
10.79
Health Care Providers & Services Industry
- Max
- 55.89
- Q3
- 30.85
- Median
- 21.17
- Q1
- 12.63
- Min
- 0.00
In the lower quartile for the Health Care Providers & Services industry, THC’s P/E Ratio of 10.79 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
ARGX
29.31
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
ARGX’s P/S Ratio of 29.31 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
THC
0.77
Health Care Providers & Services Industry
- Max
- 3.10
- Q3
- 1.74
- Median
- 0.67
- Q1
- 0.24
- Min
- 0.00
THC’s P/S Ratio of 0.77 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ARGX
5.48
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
ARGX’s P/B Ratio of 5.48 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
THC
4.36
Health Care Providers & Services Industry
- Max
- 7.61
- Q3
- 4.32
- Median
- 2.53
- Q1
- 1.14
- Min
- 0.77
THC’s P/B Ratio of 4.36 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | ARGX | THC |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 31.14 | 10.79 |
| Price-to-Sales Ratio (TTM) | 29.31 | 0.77 |
| Price-to-Book Ratio (MRQ) | 5.48 | 4.36 |
| Price-to-Free Cash Flow Ratio (TTM) | -- | 7.24 |